Viewing nowNeuRica Capsule 150 mg (Pregabalin)
Pregabalin 150mg
Hard capsule · Prescription medication
Dong-A ST Co., Ltd.

MFDS item code 201109232 · Approved 2011.10.27 · Insurance code 642506700
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used for the treatment of peripheral and central neuropathic pain in adults and is also used as an adjunct for partial seizures in patients with epilepsy. It is effective in relieving pain associated with fibromyalgia. It is utilized for the treatment of various neuropathic disorders and pain, helping improve patients' symptoms.
Administer this medicine orally as pregabalin in 2 divided doses per day, with or without food. This medicine is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function (see section 5, “Patients with renal impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section 4, “Discontinuation”). 2. Epilepsy Adults: The starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, it may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be given after each 4-hour hemodialysis session. Creatinine clearance (CLcr) ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance (CLcr) ≥30 -<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance (CLcr) ≥15 -<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance (CLcr) <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the dosing regimen. b: Supplemental dose refers to an additional dose given once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, so if symptoms of depression or mood changes occur during treatment, it is essential to inform healthcare professionals immediately. Patients should not take this medication if they are allergic to any of its components, and it should not be administered to patients with certain genetic disorders. Diabetic patients may need to adjust their blood sugar control medications due to weight gain, and if symptoms of angioedema, such as swelling of the face or around the mouth, occur due to allergic reactions, the medication should be discontinued immediately. Elderly patients may experience increased dizziness or drowsiness when taking this medication, so caution is necessary due to the risk of falls or injury. This medication may cause blurred vision or changes in vision; if such symptoms occur, stopping the medication may lead to symptom improvement. Sudden discontinuation of this medication can result in withdrawal symptoms such as insomnia, headache, and anxiety, so the dosage should be tapered gradually under a physician's guidance. There is a risk of drug abuse, so patients with a history of substance abuse should be particularly cautious, and if signs of abuse are observed, healthcare professionals must be informed immediately. Patients with impaired kidney function may require dosage adjustment of this medication. Patients with heart disease should be cautious when taking this medication, as it may cause heart problems such as congestive heart failure. Caution is necessary when taking this medication with opioid analgesics, as it may exacerbate central nervous system depressant symptoms. Patients with compromised respiratory function or the elderly may be at risk of severe respiratory depression, so dosage adjustment may be necessary. Pregnant women should use effective contraception due to the risk of fetal malformations in early pregnancy, and it is generally advisable for pregnant women to avoid taking this medication unless in special cases. Women who are breastfeeding should consider discontinuing breastfeeding or stopping the medication, as this medication can be transmitted through breast milk and may affect the infant. Caution is required when engaging in hazardous activities like driving or operating machinery until dizziness or drowsiness subsides after taking this medication. If severe rashes or blisters develop on the skin while taking this medication, it should be discontinued immediately, and healthcare advice should be sought. In cases of overdose, symptoms may include drowsiness, confusion, depression, and seizures, requiring immediate medical attention.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly closed container to protect it from air and moisture. It is best kept at room temperature between 1°C and 30°C.
This medication is a hard capsule that contains a white powder that is white or pale yellow.
30 capsules/bottle, 300 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Hard capsule · Prescription medication
Dong-A ST Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.